CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Tamoxifen - managing adverse effects - Management
Basis for recommendation
- The recommendation to advise women to be aware of symptoms of endometrial cancer and thromboembolic disease is based on the British National Formulary [BNF 56, 2008] and a safety bulletin from the Committee on Safety of Medicines [CSM, 1994; CSM, 2002].
- CKS found evidence from two large trials that the risk of endometrial cancer and thromboembolic events is increased in women taking tamoxifen compared with placebo, but the absolute numbers were small.
© NHS Institute for Innovation and Improvement